Want to see MTEX full AI Analyst Report?
Top Page
Mannatech
(NASDAQ:MTEX)
Select Model
Select Model
Rating:45Neutral
Price Target:
$5.50
▼(-30.82% Downside)
Action:Reiterated
Date:06/09/26
The score is held down primarily by weak financial performance (losses, negative cash flow, and negative equity) and heightened event-driven risk from Nasdaq equity noncompliance and going-concern/filing issues. Technicals are somewhat supportive in the short term, but valuation is constrained by loss-making results and no stated dividend support.
Positive Factors
High Gross Margin
Sustained ~75% gross margin indicates durable product economics and pricing power in supplements/skin care. With product costs low relative to revenue, margin strength supports potential recovery once below-the-gross-line costs are cut, enabling quicker path to profitability if sales stabilize.
Negative Factors
Negative Stockholders' Equity
A stockholders' deficit materially weakens the capital base and reduces financial flexibility. Negative equity makes it harder to absorb shocks, limits borrowing capacity without covenants or dilutive remedies, and forces management into potentially value‑eroding capital actions to restore solvency.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
Sustained ~75% gross margin indicates durable product economics and pricing power in supplements/skin care. With product costs low relative to revenue, margin strength supports potential recovery once below-the-gross-line costs are cut, enabling quicker path to profitability if sales stabilize.
Read all positive factors
Mannatech (MTEX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.07M
Dividend YieldN/A
Average Volume (3M)20.34K
Price to Earnings (P/E)―
Beta (1Y)0.54
Revenue Growth-7.51%
EPS Growth-6001.27%
CountryUS
Employees189
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)-6.71
Shares Outstanding1,929,670
10 Day Avg. Volume5,058
30 Day Avg. Volume20,342
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-3.00
Price to Sales (P/S)0.15
P/FCF Ratio-3.63
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue0.10
Enterprise Value/Gross Profit0.13
Enterprise Value/Ebitda8.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Mannatech Business Overview & Revenue Model
Company Description
Mannatech, Incorporated operates as a global enterprise focused on health and wellness. The company specializes in the creation, marketing, and distribution of a diverse range of products, including dietary supplements, topical skincare and anti-a...
How the Company Makes Money
Mannatech makes money primarily by selling its health and wellness products to end customers through a direct-selling distribution network. The company recognizes revenue from product sales (net of discounts/returns/allowances, where applicable) w...
Mannatech Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
22
Negative
Cash Flow
24
Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 108.04M | 117.87M | 131.96M | 137.21M | 159.76M |
| Gross Profit | 80.96M | 91.46M | 102.86M | 104.15M | 125.61M |
| EBITDA | -426.00K | 5.55M | 498.00K | 3.02M | 10.61M |
| Net Income | -15.21M | 2.49M | -2.24M | -4.49M | 9.84M |
Balance Sheet | |||||
| Total Assets | 29.99M | 36.06M | 41.21M | 49.13M | 59.63M |
| Cash, Cash Equivalents and Short-Term Investments | 6.18M | 11.40M | 7.73M | 13.78M | 24.18M |
| Total Debt | 7.36M | 6.69M | 5.71M | 6.21M | 1.83M |
| Total Liabilities | 35.22M | 27.44M | 30.72M | 34.95M | 35.21M |
| Stockholders Equity | -5.22M | 8.61M | 10.48M | 14.18M | 24.41M |
Cash Flow | |||||
| Free Cash Flow | -4.32M | 1.96M | -3.12M | -3.66M | 10.12M |
| Operating Cash Flow | -2.96M | 2.26M | -2.37M | -2.60M | 10.77M |
| Investing Cash Flow | -1.35M | -285.00K | -747.00K | -1.06M | -650.00K |
| Financing Cash Flow | -561.00K | 1.96M | -1.90M | -4.33M | -9.29M |
Mannatech Technical Analysis
Neutral
7.95
Price Trends
5.10
Positive
5.70
Negative
7.18
Negative
Market Momentum
-0.04
Positive
49.17
Neutral
43.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTEX, the sentiment is Neutral. The current price of 7.95 is above the 20-day moving average (MA) of 5.32, above the 50-day MA of 5.10, and above the 200-day MA of 7.18, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 49.17 is Neutral, neither overbought nor oversold. The STOCH value of 43.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MTEX.
Mannatech Risk Analysis
Mannatech disclosed 41 risk factors in its most recent earnings report. Mannatech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Mannatech Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
58 Neutral | $246.64M | 4.54 | 6.84% | 2.39% | -14.17% | ― | |
56 Neutral | $1.20B | -15.38 | -5.14% | 3.51% | -5.30% | -196.78% | |
50 Neutral | $136.08M | -18.92 | -9.41% | ― | -8.16% | 85.14% | |
47 Neutral | $8.68M | 0.20 | 16.79% | ― | ― | ― | |
45 Neutral | $10.07M | -0.78 | -19.54% | ― | -7.51% | -6001.27% |
* Consumer Defensive Sector Average
MTEX
Mannatech
5.22
-3.48
-40.00%
NUS
Nu Skin
5.08
-3.99
-44.01%
EPC
Edgewell Personal Care
26.00
0.01
0.05%
SKIN
Beauty Health
1.05
-0.99
-48.53%
TKLF
Yoshitsu Co. Ltd. Sponsored ADR
2.05
-1.95
-48.75%
Mannatech Corporate Events
Business Operations and StrategyExecutive/Board Changes
Mannatech Names Yasir Haider as New Chief Financial Officer
Positive
Jun 8, 2026
On June 8, 2026, Mannatech announced that its board appointed Yasir Haider as Chief Financial Officer and principal financial officer, effective June 3, 2026, succeeding former CFO James Clavijo. Haider, who joined Mannatech as Controller in Janua...
Executive/Board ChangesFinancial DisclosuresShareholder Meetings
Mannatech Shareholders Approve All Proposals at 2026 Meeting
Positive
Jun 3, 2026
Mannatech reported that shareholders passed all proposals at the 2026 annual meeting held on June 2, 2026, where 71.0% of the company’s 1,929,670 outstanding shares were represented. Investors elected John A. Seifrick and Robert Toth as Clas...
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
Mannatech Faces Nasdaq Noncompliance and Potential Delisting Risk
Negative
Apr 24, 2026
On April 20, 2026, Mannatech disclosed that it had received a notice from Nasdaq stating the company was no longer in compliance with the exchange’s minimum stockholders’ equity requirement of $2.5 million, after reporting a stockholde...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Mannatech Delays 10-K Filing Amid Going-Concern Review
Negative
Apr 2, 2026
On April 1, 2026, Mannatech, Incorporated announced it had filed a Form 12b-25 with the U.S. Securities and Exchange Commission, notifying regulators of a delayed filing of its Form 10-K for the fiscal year ended December 31, 2025. The annual repo...
Business Operations and StrategyExecutive/Board Changes
Mannatech Names Interim CFO Amid Leadership Transition
Neutral
Mar 24, 2026
On March 19, 2026, Mannatech, Incorporated decided by mutual agreement not to renew the employment contract of Chief Financial Officer James Clavijo, whose agreement is set to expire on June 30, 2026, and he will receive three months of base salar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.